Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
[Vitamin D for prevention of diseases?].
Molecular targets of FTY720 (fingolimod).
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
In vivo evidence of glutamate toxicity in multiple sclerosis.
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Olive oil phenols and neuroprotection.
Depakote: No Prescription Cheap Low
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Corticosteroids for treating optic neuritis.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Pages
« first
‹ previous
…
155
156
157
158
159
160
161
162
163
…
next ›
last »